Capecitabine + Oxaliplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Jun 1, 2006 → Nov 1, 2012
NCT ID
NCT00411229About Capecitabine + Oxaliplatin
Capecitabine + Oxaliplatin is a phase 3 stage product being developed by Roche for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00411229. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01442155 | Pre-clinical | Completed |
| NCT02560974 | Phase 3 | Completed |
| NCT00411229 | Phase 3 | Completed |
| NCT02694718 | Phase 2 | Completed |
| NCT00297141 | Phase 2 | Completed |
| NCT00216021 | Phase 2 | Completed |
Competing Products
20 competing products in Stomach Neoplasms